Compare Amgen, Inc. (AMGN) vs The Vita Coco Company Inc (COCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs The Vita Coco Company Inc — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while The Vita Coco Company Inc trades at $71.23 (market cap $4.08B). The key difference: Amgen, Inc. is far larger — about 48.1× The Vita Coco Company Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| AMGN | COCO | |
|---|---|---|
Market Cap | $196.12B | $4.08B |
Sector | Health | Technology |
52-Week High | $388.16 | $84.02 |
52-Week Low | $271.18 | $32.30 |
Enterprise Value | $241.41B | $3.89B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Vita Coco (COCO) trades at $71.40, up 0.21% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with 37.4% gross margins and 26.32% ROE, though valuation metrics appear elevated with a P/E of 51.74. Recent Q1 2026 earnings beat expectations by 47%, while analysts maintain a 60% buy rating consensus with a $78 price target. The company is scheduled to report Q2 2026 results on July 23, 2026.
COCO presents growth potential driven by market leadership in coconut water and projected revenue expansion to $659M in 2026. However, premium valuation and competitive pressures in the beverage sector warrant caution. The stock's near-term catalyst will be Q2 earnings performance against the $0.56 EPS expectation, with technical support at $69 and resistance at $73.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →
